Compartilhar
Informação da revista
Número
Vol. 42. Núm. S1.Páginas 1-78 (outubro 2020)
Speaker presentations
How clinical networking may be a powerful strategy to face the challenges faced by hematologists treating acute leukemias in the developing world. The experience of the International Consortium on Acute Leukemia (ICAL)
Eduardo M. Rego
Hematol Transfus Cell Ther. 2020;42 Supl 1:13
Open access
Oral presentations
Blinatumomab therapy in a relapsed acute lymphoblastic leukemia with isolated radius involvement following allogeneic bone marrow transplant: a case report
İbrahim Halil Açar, Yasa Gul Mutlu, Huseyin Derya Dincyurek, Birol Guvenç
Hematol Transfus Cell Ther. 2020;42 Supl 1:18
Open access
Analysis of demographic and clinical characteristics of primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis patients
P. Akyol, A. Yıldız, M. Albayrak, H. Afacan Öztürk, S. Maral, M. Reis Aras, F. YıLmaz, B. Saglam, ... U. Malkan
Hematol Transfus Cell Ther. 2020;42 Supl 1:19
Open access
The prognostic impact of comorbidity, nutritional and performance status on patients with diffuse large B cell lymphoma
B. Saglam, M. Albayrak, A. Yıldız, P. Akyol, M. Tiglioglu, M. Aras, F. YıLmaz, S. Maral, H. Ozturk
Hematol Transfus Cell Ther. 2020;42 Supl 1:21
Open access
Bendamustine-bortezomib-dexamethasone (BVD) in heavily pretreated multiple myeloma: old/new in novel agents’ era
C. Cerchione, L. Catalano, D. Nappi, S. Rocco, S. Palmieri, A. Pareto, F. Pane, F. Ferrara, G. Martinelli
Hematol Transfus Cell Ther. 2020;42 Supl 1:22
Open access
Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study
E. Terpos, A. Symeonidis, S. Delimpasi, E. Zamagni, E. Katodritou, E. Rivolti, M. Kyrtsonis, D. Fotiou, ... M. Dimopoulos
Hematol Transfus Cell Ther. 2020;42 Supl 1:22-3
Open access
A novel microrna signature with clinical significance in multiple myeloma
A. Papanota, P. Artemaki, P. Karousi, C. Liacos, M. Gavriatopoulou, E. Kastritis, C. Kontos, M. Dimopoulos, ... E. Terpos
Hematol Transfus Cell Ther. 2020;42 Supl 1:23-4
Open access
Peripheral blood immune profiling of multiple myeloma patients at diagnosis: correlations with circulating plasma cells
K. Papadimitriou, I. Ntanasis-Stathopoulos, N. Tsakirakis, M. Gavriatopoulou, I. Kostopoulos, E. Kastritis, N. Orologas-Stavrou, M. Dimopoulos, ... E. Terpos
Hematol Transfus Cell Ther. 2020;42 Supl 1:24
Open access
Long-term results of allogeneic peripheral blood hematopoietic stem cell transplantation for severe aplastic anemia
E. Aladag, H. Goker, H. Demiroglu, S. Aksu, N. Sayınalp, I. Haznedaroglu, O. Ozcebe, Y. Buyukasık
Hematol Transfus Cell Ther. 2020;42 Supl 1:27
Open access
Risk factors and outcomes related to intensive care unit admission of children with hematological and solid organ malignancies: single-center experience
C. Kaya, Z. Guzelkucuk, D. Ozyoruk, N. Ozbek, N. Yarali
Hematol Transfus Cell Ther. 2020;42 Supl 1:28
Open access
A girl with SAMD9L mutation presenting with pancytopenia, immunodeficiency and myelodsyplasia
D. Gurlek Gokcebay, I. Yaman Bajin, Y. Akcabelen, A. Koca Yozgat, O. Arman Bilir, I. Ok Bozkaya, N. Yarali, N. Ozbek
Hematol Transfus Cell Ther. 2020;42 Supl 1:29-30
Open access
The effects of vitamin D deficiency on myocardial deformation and functions in patients with β-thalassemia
A. Koca Yozgat, E. Azak, D. Kaçar, M. Işık, O. Arman Bilir, I. Çetin, N. Ozbek, N. Yaralı
Hematol Transfus Cell Ther. 2020;42 Supl 1:30
Open access
Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian cancer: a rare case report
Y. Ilhan, M. Korkmaz, E. Taskiran Guzel, K. Mammadova, S. Sezgin Goksu, A. Tatlı, H. Coskun
Hematol Transfus Cell Ther. 2020;42 Supl 1:33
Open access
Poster presentations
Hypercalcemia due to the interaction between all trans retinoic acid and posaconazole used for acute promyelocytic leukemia treatment
H. Afacan Öztürk, M. Albayrak, S. Maral, M. Reis Aras, F. YıLmaz, P. Akyol, M. Tiglioglu
Hematol Transfus Cell Ther. 2020;42 Supl 1:35
Open access
Acute phase reactants in chronic inflammation leading to secondary myelofibrosis in polycythemia vera and essential thrombocytosis
E. Aladag, I. Haznedaroglu, N. Sayinalp, H. Demiroglu, H. Goker, S. Aksu, O. Ozcebe, A. Ayhan, Y. Buyukasik
Hematol Transfus Cell Ther. 2020;42 Supl 1:42
Open access
Disease and clinical characteristics of patients with chronic myeloproliferative neoplasms: 11-year single center experience
P. Akyol, A. Yıldız, H. Afacan Öztürk, S. Maral, M. Reis Aras, F. Yılmaz, B. Saglam, M. Tıglıoglu, M. Albayrak
Hematol Transfus Cell Ther. 2020;42 Supl 1:43
Open access
The frequency of calreticulin and mpl gene mutations in bcr-abl and jak2 unmutated chronic myeloproliferative neoplasms and its effect on the outcome
T. Tiryaki, A. DağLar Aday, M. Güzel Mastanzade, M. ÖZbalak, D. Özlük, F.Y. Onal Hindilerden, M. Yenerel, A. Yavuz, ... M. Nalçacı
Hematol Transfus Cell Ther. 2020;42 Supl 1:43
Open access
Prognostic value of pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratio in diffuse large B-cell lymphoma: a single-center experience
G. Dagci, M. Guzel Mastanzade, M. Ozbalak, D. Ozluk, T. Tiryaki, I. Yonal Hindilerden, M. Yenerel, M. Nalcaci, S. Kalayoglu Besisik
Hematol Transfus Cell Ther. 2020;42 Supl 1:48-9
Open access
Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study
M. Turgut, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, ... T. Martin
Hematol Transfus Cell Ther. 2020;42 Supl 1:51-2
Open access
Monoclonal gammopathy of undertemined significance and solitary plasmacytoma: progression factors in population of gomel region in belarus
Z. Kozich, V. Martinkov, D. Zinovkin, Z. Pugacheva, M. Zhandarov, L. Smirnova
Hematol Transfus Cell Ther. 2020;42 Supl 1:53-4
Open access
Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
C. Cerchione, L. Catalano, D. Nappi, G. Musuraca, A. Lucchesi, S. Ronconi, A. Pareto, F. Pane, G. Martinelli
Hematol Transfus Cell Ther. 2020;42 Supl 1:55
Open access
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
C. Cerchione, L. Catalano, D. Nappi, G. Musuraca, A. Lucchesi, S. Ronconi, F. Pane, G. Martinelli
Hematol Transfus Cell Ther. 2020;42 Supl 1:55-6
Open access
Safety of caplacizumab in patients without documented severe adamts13 deficiency during the hercules study
S. Besisik, J. De La Rubia, F. Peyvandi, M. Scully, S. Cataland, P. Coppo, J. A. Kremer Hovinga, P. Knoebl, ... F. Callewaert
Hematol Transfus Cell Ther. 2020;42 Supl 1:62
Open access
Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura
L. Kaynar, P. Coppo, M. Scully, J. De La Rubia, F. Peyvandi, S. Cataland, J. A. Kremer Hovinga, P. Knoebl, ... R. De Passos Sousa
Hematol Transfus Cell Ther. 2020;42 Supl 1:62-3
Open access
Multiple relapsed acute lymphoblastic leukemia with t(9;13) in a child
D. Gurlek Gokcebay, Y. Akcabelen, A. Koca Yozgat, D. Kacar, O. Arman Bilir, M. Isik, I. Ok Bozkaya, N. Ozbek, N. Yarali
Hematol Transfus Cell Ther. 2020;42 Supl 1:72
Open access
Acute lymphoblastic leukemia with ebv infection and multiple chromosomal abnormalities in a child
D. Kacar, A. Koca Yozgat, S. Sahin, Y. Akcabelen, F. Kurtipek, D. Gurlek Gokcebay, N. Yarali
Hematol Transfus Cell Ther. 2020;42 Supl 1:73
Open access
Acute lymphoblastic leukemia in the context of constitutional mismatch repair deficiency syndrome: a case report
D. Kacar, A. Koca Yozgat, S. Sahin, Y. Akcabelen, F. Kurtipek, D. Gurlek Gokcebay, N. Yarali
Hematol Transfus Cell Ther. 2020;42 Supl 1:74
Open access
Isolated extramedullary relapse after hematopoietic stem cell transplantation
Z. Guzelkucuk, P. Isık, O. Arman Bilir, D. Kacar, A. Koca Yozgat, M. Isık, D. Gurlek Gokcebay, I. Ok Bozkaya, ... N. Yarali
Hematol Transfus Cell Ther. 2020;42 Supl 1:77
Open access
Publicar em
Hematology, Transfusion and Cell Therapy
A revista pertence ao Committee on Publication Ethics (COPE) www.publicationethics.org e adere aos seus princípios e procedimentos.